Your trusted CDMO partner based in Europe
Specialized in small-molecule dosage-form development, reformulation and EU-GMP manufacturing.
A reliable partner for global markets
Human and Veterinary
The agility of a mid-sized CDMO
A reliable partner for global markets
Human and Veterinary
The agility of a mid-sized CDMO
CDMO PARTNERSHIP FOR
We join your project at the stage you need.
Whether you need support at the beginning, mid-way or close to commercial production, we slot into your process and keep your project moving smoothly.
70% of our clients are based in Europe and 30% overseas. We know what it takes to run international projects efficiently. Ready to explore how we can support your next phase? Talk to our Experts!
Learn More About our Capababilities - Human and Veterinary CDMO
We provide end-to-end support in formulation, reformulation, analytical services, scale-up and EU-GMP manufacturing, for both sterile and non-sterile products in human and animal health.
Dosage Forms for Export
We stand out for our know-how in niche dosage forms, both sterile and non- sterile, such as powders for injection, nasal sprays and ophthalmic ointments.
Sterile vial capabilities (liquids & powders)
BePharBel Manufacturing has strong expertise in sterile drug manufacturing. Our aseptic area is a controlled atmosphere zone (A class) in compliance with the EN/ISO14644-1 standard.
- Annual production : 3 million glass vials
- Bulk batch size : 450 L (liquid) or 28 kg (powder)
Nasal sprays
- Annual production : 8 million vials
- Packaging : dropper, dosing spray (in glass or plastic)
- Bulk batch size : 1 000 L
Ophthalmic ointments
- Annual production : 1,5 million aluminum tubes
- Bulk batch size : 200 kg
Tablets and capsules
Tablets
- Annual production : 50 million tablets in blisters or bottles
- Bulk batch size : 210 kg
Capsules
- Annual production : 10 million capsules in blisters or bottles
- Bulk batch size : 210 kg
Export Focus & Networking
Belgium as Strategic Location & our International Reach
-
Why Belgium for your project?
By choosing BePharBel Manufacturing as your CDMO partner, you enter a leading European pharmaceutical ecosystem.
Belgium is among Europe’s top pharmaceutical producers and exporters, offering a dense network of pharma companies, research institutions and logistics platforms.
BePharBel Manufacturing benefits from MRAs with Canada, Japan, and other markets, enabling you to supply multiple regions from a single site.
Looking to transfer your production, scale up or enter the european market?
-
Scientific and Industrial Partners
Within this ecosystem, we collaborate with academic and industry partners that reinforce our R&D and support our visibility in Europe.
Our Facilities
One site, one quality system, one audit
Our 12,000 m² EU-GMP site in Courcelles brings together R&D, formulation, analytical methods, pilot scale and full commercial production on one EU-GMP site.
Your project stays with the same equipment, documentation and QA/QP team from lab scale to commercial batches, avoiding inter-site transfers, duplicate validation work and additional audits.
Sustainability in action
- 530 m² of photovoltaic panels
- Enhanced waste reduction and sorting initiatives
- Activated-carbon filtration for industrial wastewater
- Gradual transition to an all-electric vehicle fleet
Partner-Focused CDMO Team
Built for long-term collaboration
BePharBel Manufacturing is an independent Belgian SME with a mix of public and private shareholders and no venture-capital ownership. This stable structure supports a long-term vision aligned with the long lifecycles of pharmaceutical development. We prioritise partnership over one-off projects and rely on transparent communication to build durable relationships.
- Transparent communication
- Stable governance, free from short-term investor pressure
- Dedicated contact over the long-term
- Fast decisions and straightforward collaboration
Our multidisciplinary team brings solid experience in pharmaceutical development, manufacturing, quality and regulatory affairs. We work closely with you to understand your product, anticipate challenges and find pragmatic solutions.
